The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis

GP Amminger; B Nelson; C Markulev; HP Yuen; MR Schäfer; M Berger; N Mossaheb; M Schlögelhofer; S Smesny; IB Hickie; GE Berger; EYH Chen; L de Haan; DH Nieman; M Nordentoft; A Riecher-Rössler; S Verma; A Thompson; AR Yung; PD McGorry

Journal article

The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis

GP Amminger, B Nelson, C Markulev, HP Yuen, MR Schäfer, M Berger, N Mossaheb, M Schlögelhofer, S Smesny, IB Hickie, GE Berger, EYH Chen, L de Haan, DH Nieman, M Nordentoft, A Riecher-Rössler, S Verma, A Thompson, AR Yung, PD McGorry

Biological Psychiatry | ELSEVIER SCIENCE INC | Published : 2020

DOI: 10.1016/j.biopsych.2019.08.030

Abstract

Background: NEURAPRO was a multicenter, placebo-controlled trial of long-chain omega-3 polyunsaturated fatty acids (n-3 PUFAs) (fish oil) in 304 individuals at ultra-high risk for psychotic disorders. The study failed to show benefits of n-3 PUFAs over placebo. Although the randomized controlled trial design is placed at the top of the evidence hierarchy, this methodology has limitations in fish oil randomized controlled trials, as not only is the test agent present in the intervention group, but also n-3 fats are present in the diet and the body tissue of all participants. Methods: Analysis of biomarker data (eicosapentaenoic acid [EPA], docosahexaenoic acid [DHA], n-3 index, EPA+DHA) colle..

View full abstract

University of Melbourne Researchers

Paul Amminger Author

Barnaby Nelson Author

Connie Markulev Author

Hok Yuen Author

Related Projects (5)

EMERGING MENTAL DISORDERS IN YOUNG PEOPLE: USING CLINICAL STAGING FOR PREDICTION, PREVENTION AND EARLY INTERVENTION

Mental disorders are a major cause of disability in Australia, especially for young people. We have developed a clinical staging model cover..

LIPID BIOLOGY FOR PREDICTION AND PREVENTION OF PSYCHOTIC DISORDERS AND PERSISTENT DEPRESSION IN YOUNG PEOPLE

My vision for the next 5 years is to establish ω-3PUFAs as a first-line treatment for indicated prevention of psychosis and persistent depre..

MAPPING AND TREATING EARLY CLINICAL STAGES OF MENTAL DISORDERS DURING TRANSITION TO ADULTHOOD

The research proposed in this Fellowship is aimed at young people with emerging mental ill-health. The specific goals and targets are to for..

CLINICAL PREDICTORS OF OUTCOME IN THE ULTRA HIGH RISK FOR PSYCHOSIS ("PRODROMAL") POPULATION

This area of research is concerned with improving our ability to identify young help-seeking patients who are most at risk of developing psy..

RCT OF OMEGA-3 FATTY ACIDS AS TREATMENT OF SUBTHRESHOLD SYMPTOMS IN YOUNG PEOPLE AT ULTRA-HIGH RISK FOR PSYCHOSIS

Omega-3 fats are a type of polyunsaturated fat which has long been thought to be beneficial for health. The body cannot make its own omega-3..

Grants

Awarded by Bristol-Myers Squibb

Funding Acknowledgements

This work was supported by the Stanley Medical Research Institute (Grant No. 07TGF-1102 [to PDM, GPA, and BN]), National Health and Medical Research Council Australia (Grant No. 566529 [to PDM, IBH, ARY, and GPA], Grant No. 509388 [to GPA and PDM], Senior Research Fellowship Grant No. 1080963 [to GPA], Senior Research Fellowship Grant No. 566593 [to ARY], Career Development Fellowship Grant No. 1027532 [to BN], and Senior Principal Research Fellowship Grant No. 1060996 [to PDM]), Colonial Foundation (to PDM), and National Alliance for Research on Schizophrenia and Depression (to PDM). PDM reports receiving unrestricted research funding from AstraZeneca, Eli Lilly and Company, Janssen-Cilag, Pfizer, and Novartis and honoraria for educational activities with AstraZeneca, Eli Lilly and Company, Janssen-Cilag, Pfizer, Bristol-Myers Squibb, Roche Holding AG, and the Lundbeck Institute. The other authors report no biomedical financial interests or potential conflicts of interest.